沙库巴曲-缬沙坦治疗慢性心力衰竭患者的临床观察  

Clinical Observation on the Treatment of Patients with Chronic Heart Failure by Sacubatre Valsartan

作　　者：徐志伟[1] 陈伟峰[1] 张宪华[1] 王滨[1] 郑晓英[1] 彭文龙 XU Zhi-wei;CHEN Wei-feng;ZHANG Xian-hua;WANG Bin;ZHENG Xiao-ying;PENG Wen-long(Emergency Ward Emergency ICU,Shenzhen Second People’s Hospital,Shenzhen 518035,China)

机构地区：[1]深圳市第二人民医院急诊病房急诊ICU,广东深圳518035

出　　处：《南昌大学学报（医学版）》2021年第3期58-61,共4页Journal of Nanchang University：Medical Sciences

摘　　要：目的观察沙库巴曲-缬沙坦对慢性心力衰竭患者心功能改善的效果。方法将60例慢性心力衰竭患者随机分为观察组和对照组,每组30例。观察组予沙库巴曲缬沙坦钠片+琥珀酸美托洛尔缓释片+螺内酯治疗,对照组予盐酸贝那普利片+琥珀酸美托洛尔缓释片+螺内酯治疗,比较2组治疗前和治疗1、2、6个月后的主要心功能指标(左室射血分数、左室舒张期内径、N-末端pro-B型利尿钠肽)水平及不良反应发生率。结果治疗前2组左室射血分数、左室舒张期内径、NT-proBNP比较差异无统计学意义(P>0.05)。治疗1、2、6个月后2组左室射血分数、左室舒张期内径、NT-proBNP水平均较治疗前明显改善(P<0.05)。治疗1个月后2组主要心功能指标比较差异无统计学意义(P>0.05),治疗2、6个月后观察组主要心功能指标明显优于对照组(P<0.05)。2组主要心功能指标(对照组除外左室舒张期内径)治疗6个月优于治疗2个月、治疗2个月优于治疗1个月(P<0.05)。观察组肌酐升高和总不良反应发生率明显低于对照组(13.33%比26.67%,33.33%比46.67%,P<0.05)。结论应用沙库巴曲-缬沙坦的治疗方案在改善慢性心力衰竭患者心功能方面优于传统治疗方案,尤其在远期治疗效果和预后方面优于传统治疗方案。Objective To observe the effect on improving the heart function in patients with chronic heart failure treated by sacubitril-valsartan.Methods Sixty patients with CHF admitted to the emergency ward of our department were divided into observation group and control group(30 cases/group),and the observation group was given sacubitril-valsartan+betaloc+aspironolactone treatment,the control group was treated with with benazepril+betaloc+aspironolactone.The main cardiac function indexes,include left ventricular ejection fraction,left ventaricular diastolic diameter,and NT-proBNP of the two groups were evaluated and compared before treatment,and after treating 1 month,2 months,and 6 months.Results The main cardiac function indexes of the two groups after treatment were significant improvement(P<0.05),the degree of improvement of LVEF,LVEDD,and NT-proBNP in the observation group which used sacubitril-valsartan were better than the control group,especially after 6 months of treatment(P<0.05),and it has statistically significant.Conclusion The cardiac function of patients with heart failure was significantly improved in both groups.The observation group added sacubitril-valsartan is superior to the control group treated by the traditional treatment method in improving the heart function of patients with CHF especially,long-term treatment’s effect and prognosis.

关 键 词：沙库巴曲-缬沙坦 左室射血分数 左室舒张期内径 N-末端pro-B型利尿钠肽 

分 类 号：R541.6[医药卫生—心血管疾病]